Results 1 to 10 of about 1,058,449 (296)

The microbiota-gut-brain axis and central nervous system diseases: from mechanisms of pathogenesis to therapeutic strategies. [PDF]

Front Microbiol
Xu J, Lu Y.
europepmc   +3 more sources

Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment

Journal of Translational Medicine, 2023
Background Glioblastoma (GBM) is a brain tumor with the highest level of malignancy and the worst prognosis in the central nervous system. Mitochondrial metabolism plays a vital role in the occurrence and development of cancer, which provides critical ...
Tongxuan Guo, Changyong Wu, Lingni Zhou, Junhao Zhang, Wanzhou Wang, Yang Shen, Ludong Zhang, Mingshan Niu, Xu Zhang, Rutong Yu, Xuejiao Liu   +10 more
doaj   +1 more source

YAP promotes autophagy and progression of gliomas via upregulating HMGB1

Journal of Experimental & Clinical Cancer Research, 2021
Background Due to the hypoxia and nutrient deficiency microenvironment, glioblastoma (GBM) exhibits high autophagy activity and autophagy plays an important role in the progression of GBM.
Min Zhao, Yu Zhang, Yang Jiang, Kai Wang, Xiang Wang, Ding Zhou, Yan Wang, Rutong Yu, Xiuping Zhou   +8 more
doaj   +1 more source

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma

Drug Delivery, 2023
Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties.
Haoyue Xu, Yongkang Zhang, Linfeng Li, Yanhong Ren, Feng Qian, Lansheng Wang, Hongwei Ma, Ankang Quan, Hongmei Liu, Rutong Yu   +9 more
doaj   +1 more source

Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma

Cell Communication and Signaling, 2023
Background Glioblastoma multiforme (GBM) is a devastating disease that lacks effective drugs for targeted therapy. Previously, we found that the third-generation epidermal growth factor receptor (EGFR) inhibitor AZD-9291 persistently blocked the ...
Tongxuan Guo, Changyong Wu, Junhao Zhang, Jiefeng Yu, Guoxi Li, Hongyan Jiang, Xu Zhang, Rutong Yu, Xuejiao Liu   +8 more
doaj   +1 more source

GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma

Cell Death Discovery, 2022
Glioblastoma multiforme (GBM) is the most aggressive malignant primary brain tumor of the central nervous system. Despite continuous progression in treatment options for GBM like surgery, radiotherapy, and chemotherapy, this disease still has a high rate
Xu Zhang, Runqiu Wu, Cong Tian, Wanzhou Wang, Lingni Zhou, Tongxuan Guo, Jiefeng Yu, Changyong Wu, Yang Shen, Xuejiao Liu, Rutong Yu   +10 more
doaj   +1 more source

Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop

Journal of Experimental & Clinical Cancer Research, 2023
Background After diagnosis, glioblastoma (GBM) patients undertake tremendous psychological problems such as anxiety and depression, which may contribute to GBM progression.
Yan Wang, Xiang Wang, Kai Wang, Ji Qi, Yu Zhang, Xu Wang, Long Zhang, Yi Zhou, Linbo Gu, Rutong Yu, Xiuping Zhou   +10 more
doaj   +1 more source

Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation

Journal of Nanobiotechnology, 2021
Background The postoperative recurrence of malignant gliomas has presented a clinical conundrum currently. Worse, there is no standard treatment for these recurrent tumours.
Yufu Zhu, Jun Jia, Gang Zhao, Xuyang Huang, Lansheng Wang, Yongkang Zhang, Long Zhang, Naveena Konduru, Jun Xie, Rutong Yu, Hongmei Liu   +10 more
doaj   +1 more source

Delayed diagnosis of the neuromyelitis optica spectrum disorder

Неврология, нейропсихиатрия, психосоматика, 2023
Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory demyelinating diseases of the central nervous system. In 2015, International Expert Panel established diagnostic criteria for NMOSD.
S. A. Dzhukkaeva, E. V. Ermilova, Sh. R. Nabiev, O. N. Voskresenskaya   +3 more
doaj   +1 more source

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Journal of Hematology & Oncology, 2016
Background Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative.
Xuejiao Liu, Yulong Chong, Yiming Tu, Ning Liu, Chenglong Yue, Zhenglei Qi, Huize Liu, Yao Yao, Hongmei Liu, Shangfeng Gao, Mingshan Niu, Rutong Yu   +11 more
doaj   +1 more source